Compare MCBS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | VTYX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.1M | 990.9M |
| IPO Year | 2019 | 2021 |
| Metric | MCBS | VTYX |
|---|---|---|
| Price | $28.58 | $13.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 7 |
| Target Price | ★ $31.00 | $13.50 |
| AVG Volume (30 Days) | 60.2K | ★ 3.1M |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 24.75 | ★ 40.30 |
| EPS | ★ 1.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.76 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.24 | $0.90 |
| 52 Week High | $31.00 | $15.34 |
| Indicator | MCBS | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 72.58 |
| Support Level | $26.90 | $13.89 |
| Resistance Level | $29.00 | $14.07 |
| Average True Range (ATR) | 0.68 | 0.03 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 17.29 | 88.89 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.